Comparison of the effects of muzolimine and furosemide in patients with end-stage renal failure on chronic dialysis.
The pharmacodynamic effects of muzolimine and furosemide were compared in a single dose cross-over study in 8 patients on regular dialysis treatment, who had a residual diuresis of more than 300 ml/day. The study periods comprised two dialysis-free intervals of 3 days. On the second dialysis-free day either muzolimine 240 mg or furosemide 240 mg was administered orally. Urine was collected in 12-h periods on the pre-treatment, treatment and post-treatment days, and the excretion of sodium, potassium, urea and creatinine were measured. After administration of muzolimine 240 mg urine volume rose to twice that of the previous day, and sodium excretion increased approximately threefold. In contrast, the effect of furosemide 240 mg was not a pronounced; the diuresis was only 1.6 times that on the previous day and natriuresis was only 2.2 times as large. Excretion of potassium and creatinine was only slightly increased by either substance. The elimination of urea was increased by both substances to the same degree as the corresponding increase in diuresis.
D003404:Creatinine / Q000378:metabolism; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D009156:Muzolimine / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects; D012964:Sodium / Q000378:metabolism; D014508:Urea / Q000378:metabolism
D011720:Pyrazoles; D009156:Muzolimine; D005665:Furosemide; D014508:Urea; D012964:Sodium; D003404:Creatinine